Formato .PDF

30. Yprianou A, Scott HC, Shah R, Fein AM. The challenging of nonresolving pneumonia.
Knowing the norms of radiographic resolution is key. Postgrad Med 2003;113(1): 25-32.
31. Ewig S, Ruiz M, Mensa J, Marcos MA, Martinez JA, Arancibia F, Niederman MS, Torres A.
Severe community-acquired pneumonia: assessment of severity criteria. Am J Respir Crit
Care Med 1998;158:1102-8.
32. Mandell LA, Bartlett JG, Scott DF, File TM, Musher DM, Whitney C. Update of practice
guidelines for the management of community-acquired pneumonia in immunocompetent adults.
Clin Infect Dis 2003;37:1405-33.
33. Berntsson E, Lagergard T, Strannegard O, Trollfors B. Etiology of community acquired
pneumonia in outpatients. Eur J Clin Microbiol 1986;5:446-7.
34. Marrie TJ, Peeling RW, Fine MJ, Singer DE, Coley CM, Kapoor WN. Ambulatory patients with
community-acquired pneumonia: the frequency of atypical agents and clinical course. Am J
Med 1996;101:508-15.
35. Eaton MD, Meiklejohn G, van Eric W. Studies on the etiologies of primary atypical pneumonia:
A filtrable agent transmisible to cotton rats, hamster, and chick embryos. J Exp Med 1944;
79:649-68.
36. Chanock RM, Dienes L, Eaton M. Mycoplasma pneumoniae: proposed nomenclature for
atypical pneumonia organism (Eaton agent). Science 1963;140:662-7.
37. Marston BJ, Plouffe JF, File TM, Hackman BA, Salstrom SJ, Lipman HB, Kolczak, MS,
Breiman RF. Incidence of community-acquired pneumonia requiring hospitalization: results of
a population-based active surveillance study in Ohio. The Community-Based Pneumonia
Incidence Study Group. Arch Intern Med 1997;157:1709-18.
38. Lieberman D, Schlaeffer F, Boldur I, Lieberman D, Horowitz S, Friedman MG, et al. Multiple
pathogens in adult patients admitted with community-acquired pneumonia: a one year
prospective study of 346 consecutive patients. Thorax 1996;51:179-84.
39. Samama MM. A comparison of enoxaparin with placebo for the prevention of
thromboembolism in acutely ill medical patients. Prophylaxis in medical patients with
enoxaparin study group. N Engl J Med 1999;341:793-800.
40. Clagett GP. Prevention of venous thromboembolism. Chest 1998;114(5 Suppl):531S-60S.
41. Nicolaides AN. Consensus statement. Prevention of venous thromboembolism. Int Angiol
1997;16:3-38.
42. Goldhaber SZ. DVT prevention: What is happening in the “real world”? Semin Thromb Hemost
2003;29(Suppl 1):23-31.
43. Goldhaber SZ, et al. A prospective registry of 5,451 patients with ultrasound-confirmed deep
vein thrombosis. Am J Cardiol 2004;93:259-62.
44. Gardund B. For the heparin prophylaxis study group. Randomized, controlled trial of low-dose
heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. Lancet
1996;347:1357-61.
45. Kumthorn M, Coque TM, Singh KV, Barbara EM. In vitro activities of two ketolides, HMR
3647 and HMR 3004, against gram-positive bacteria. Antimicrob Agents Chemother
1999;43(4):930-6.
46. Bertho G. Conformational analysis of ketolide, conformations of RU 004 in solution and bound
to bacterial ribosomes. J Med Chem 1998;27:3373-86.
47. Hansen LH. The macrolide-ketolide antibiotic binding site is formed by structures in domains II
and V of 23S ribosomal RNA. Mol Microbiol 1999;31:623-31.
48. Leclercq R. Will resistance to ketolides develop in Streptococcus pneumoniae? Antimicrob
Agents Chemother. 2002;46:2727-2734.
49. Panduch GA. Susceptibilities of penicillin and erythromycin susceptible and resistant
pneumococci to MHR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17
other agents. Antimicrob Agents Chemother 1998;42:624-30.
50. Wooton M. Guidelines for CAP in adults o CID 2003:37 (1 December) ó 000 vitro activity of
HMR 3647 against Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis
and Beta-hemolytic streptococci. J Antimicrob Chemother. 1999;44:445-53.
51. Edelstein PH, Edelstein MA. In-vitro activity of the ketolide HMR 3647 (RU 6647) for
Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs
with Legionella pneumophila pneumonia. Antimicrob Agents Chemother 1999; 43:90-5.